Seaside Therapeutics Reports Data From Randomized, Placebo-Controlled Phase 2 Study In Fragile X Syndrome

28 July 2010, 4:40 am

Seaside Therapeutics, Inc. announced data from the largest randomized, placebo-controlled study conducted to date in individuals with fragile X syndrome. In a Phase 2 study of STX209, clinically meaningful improvements on global and specific neurobehavioral outcomes were observed in the general study population. The improvements were statistically significant in pediatric patients with more ...... Read More »

More Topics from "Articles"

• The Pits
• 36 Hours in East Hampton
• 36 Hours: East Hampton
• Area Events
• [news] Get Involved: Public Citizen - Monterey County Weekly
• Sports briefs: Former CSUMB golfer qualifies for U.S. Amateur
• Golf notebook: Champions' Q-School coming to Bayonet
• Jolie and Stallone not welcome at geekfest
• California American Water to Host Vendor Diversity Business Expo